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Abstract: Extracellular vesicles (EVs), e.g., exosomes and microvesicles, are one of the main networks
of intercellular communication. In myeloproliferative neoplasms, such as polycythemia vera (PV),
excess of EVs originating from overabundant blood cells can directly contribute to thrombosis through
their procoagulant activity. However, the proteomic composition of these vesicles in PV patients has
not been investigated before. In this work, we examined the proteomic composition of serum EVs of
PV patients in comparison to healthy controls. We processed EV-enriched serum samples using the
Multiple Enzyme Filter Aided Sample Preparation approach (MED-FASP), conducted LC-MS/MS
measurements on a Q-Exactive HF-X mass spectrometer, and quantitatively analyzed the absolute
concentrations of identified proteins by the Total Protein Approach (TPA). Thirty-eight proteins were
present at statistically significant different concentrations between PV patients’ study group and
healthy controls’ group. The main protein components deregulated in PV were primarily related
to excessive amounts of cells, increased platelet activation, elevated immune and inflammatory
response, and high concentrations of procoagulant and angiogenic agents. Our study provides the
first quantitative analysis of the serum EVs’ proteome in PV patients. This new knowledge may
contribute to a better understanding of the secondary systemic effects of PV disease and further
development of diagnostic or therapeutic procedures.
Keywords: extracellular vesicles; polycythemia vera; proteomics; total protein approach;
multi-enzyme digestion filter aided sample preparation (MED-FASP)
1. Introduction
The means by which cells within a tissue, an organ, or whole organism communicate play
a key role in shaping physiologically relevant cellular responses. Cell-to-cell communication is a
fundamental component of both normal physiology and pathophysiology. One of the mechanisms by
which cells communicate is the generation and processing of extracellular vesicles [1]. Extracellular
vesicles (EVs), including exosomes and microvesicles (MVs), are released by diverse cell types
both in healthy and diseased tissues [2,3]. Exosomes promote directed and random cell motility,
invasion, and serum-independent growth. These small vesicles (approximately 50–100 nm in diameter),
which were present inside large multivesicular endosomes, appear to arise through unfolding and
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budding from the limiting membrane of late endosomes. The biogenesis of exosomes determines
their membrane orientation [4,5]. For instance, exosomes from reticulocytes contain the transferrin
receptor, which is absent in mature erythrocytes. The transferrin receptor is a marker of immature
erythrocytes, internalized from a plasma membrane, which might be used to follow endocytosis and
the recycling of cell surface proteins. This process results in the gain of vesicles that contain the cytosol
and which have exposed the extracellular domain of the transferrin receptor on their surface [1,4].
The exosome-mediated information transfer allows for the crosstalk of cells within the hematopoietic
system and for interactions between hematopoietic cells and local or distant tissue cells. The molecular
and genetic mechanisms that exosomes utilize to shuttle information between cells are currently being
examined as well as the potential roles exosomes play as biomarkers of disease or future therapeutic
targets [6].
Although the role of EVs in patients with hematologic malignancies has not been studied so
extensively as compared to solid cancer studies [7–10], exosomes have been reported to play a crucial
role in every aspect of the communication, development, functional integrity, and progression to
the hematologic malignancy [6]. These vesicles can reprogram the bone marrow microenvironment,
creating a place for abnormal cells and promoting their expansion. As reported for solid cancer,
serum/plasma of patients with hematologic malignancies is enriched in exosomes in comparison with
healthy volunteers. Particularly, newly diagnosed patients with acute myeloid leukemia (AML) or
chronic lymphocytic leukemia (CLL) have significantly higher serum levels of exosomes (measured
by the amount of protein in plasma-isolated exosomes) compared to levels in the serum of healthy
controls [11]. Furthermore, increased levels of platelet derived microparticles have been reported
in patients with myeloproliferative neoplasms, such as polycythemia vera (PV) [12–15]. PV is a
heterogeneous disease of stem cells with preferential increase in the number of erythrocytes, which
through resulting increased viscosity in combination with other pathogenic factors, may lead to
thromboembolic complications. This neoplasm is etiologically linked to a somatic mutation in the
JAK2 gene (JAK2V617F), which is found in about 90% of patients with PV, and in about 50% of
essential thrombocythemia (ET) and primary myelofibrosis (MF) [16]. The World Health Organization
(WHO) classified the classic myeloproliferative diseases as neoplastic due to their clonality with
additional revisions in 2016 [17]. On the other hand, somatic mutations in the endoplasmic reticulum
chaperone gene (CALR) are detectable in a majority of myeloproliferative neoplasms (MPN) patients
with non-mutated JAK2 and in a small proportion of MPN somatic mutations in the MPL gene have
been also reported [18,19]. There are two mechanisms of a hypercoagulable state associated with
PV–firstly, involving the abnormal components of the hematopoietic system (platelets, erythrocytes
and leucocytes) which are derived from the clonal proliferation of the hematopoietic progenitor cells
and prothrombotic phenotype; secondly, inflammatory response from the host towards cytokines and
the inflammatory mediators released by malignant cells [20–22]. Although it is known that extracellular
vesicles released from cell membranes and circulating in the blood can directly contribute to thrombosis
through their procoagulant activity, the potential association between the proteomic composition of
EVs and the risk of thrombotic events in PV has not been described before.
The involvement of EVs in the intercellular communication and molecular programming of
different cell types creates a demand for a straight characterization of the proteomes that those vesicles
deliver to cells. In this work, we decided to compare the proteomic profiles of EVs purified from
the serum of patients suffering from polycythemia vera and healthy volunteers using proteomics
methods (see Figure 1), i.e., Multiple Enzyme Filter Aided Sample Preparation (MED-FASP) [23],
liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) measurements, and Total
Protein Approach (TPA) [24].
Proteomes 2019, 7, 20 3 of 17
Proteomes 2019, 7, x FOR PEER REVIEW 3 of 18 
 
 
Figure 1. Overview of the analytical workflow: (A) Isolation of extracellular vesicles (EVs) from blood 
samples; (B) multi-enzyme digestion filter aided sample preparation (MED-FASP) digestion protocol 
and liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) analysis of the 
samples. 
2. Materials and Methods  
2.1. Blood Collection and Serum Isolation 
Blood samples were collected into the 8.5 mL BD Vacutainer™ Venous Blood Collection Tubes: 
SST™ Serum Separation Tubes. In total, 18 samples were collected: Nine from patients diagnosed 
with polycythemia vera (diagnosed by WHO 2016 criteria) and nine control samples from healthy 
donors. All patients were on phlebotomy and aspirin treatment. Each donor gave written consent 
regarding the use of collected material in translational studies and the publication of obtained results. 
Examination of patient blood samples had been approved by Ludwig-Maximilians-Universität ethics 
committee. Leukocyte, platelet, and cholesterol blood concentrations of patients taking part in the 
study are listed in Supplementary Table 1a. Blood samples were allowed to clot at room temperature 
for 30 min after collection. The serum was separated from the clot by centrifugation at room 
temperature for 10 min at 2000 g. Then, the serum was transferred into a new tube, frozen by liquid 
nitrogen and stored in −80°C until EV extraction. 
2.2. Extracellular Vesicle Isolation 
EVs were isolated from the blood serum using the Total Exosome Isolation (from serum) reagent 
(Invitrogen) according to the manufacturer’s procedure (Figure 1a). Samples were thawed at room 
temperature and centrifuged at 2000 g for 30 min to remove cells and debris. Supernatant containing 
the clarified serum was transferred to new tubes and placed on ice prior to the procedure. Briefly, 
500 µL of serum was mixed with 100 µL of reagent and incubated at 4 °C for 30 min. Afterwards, 
samples were centrifuged at 10,000 g for 10 min at room temperature. Supernatant was discarded, 
and the pellet containing EVs was dissolved in 100 µl of PBS buffer. A 1% SDS buffer (100 mM Tris-
HCl pH 8, 50 mM DTT, 1% SDS) was used at the ratio of 1:5 (EVs: buffer) for 10 min at 95 °C to lyse 
obtained EVs and reduce disulfide bonds of released proteins. Lysed EVs were frozen by liquid 
nitrogen and stored at −20 °C until further processing. 
2.3. Protein Digestion 
Samples containing lysed EVs were subjected to digestion by the MED-FASP (Multi-Enzyme 
Digestion Filter Aided Sample Preparation) procedure (Figure 1b) [23]. Total protein concentration 
was measured using the tryptophan fluorescence-based (WF) assay [25] (see Supplementary Table 
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2. Materials and Methods
2.1. Blood Collection and Serum Isolation
Blood samples were collected into the 8.5 mL BD Vacutainer™ Venous Blood Collection Tubes:
SST™ Serum Separation Tubes. In total, 18 samples were collected: Ni e from patients diagnos d with
polycythemia vera (diagnosed by WHO 2016 criteria) and nine control samples from healthy donors.
All patients were on phlebotomy and aspirin treatment. Each donor gave written consent regarding the
use of collected material in translational studies and the publication of obtained results. Examination
of patient blood samples had been approved by Ludwig-Maximilians-Universität ethics committee.
Leukocyte, platelet, and cholesterol blood concentrations of patients taking part in the study are listed
in Supplementary Table S1a. Blood samples were allowed to clot at room temperature for 30 min after
collection. The serum was separated fro the clot by centrifugation at room emperature f r 10 min
at 2000 g. Then, the serum was transf rred into a new tube, f oze by liquid nitrog and stored in
−80 ◦C until EV extraction.
2.2. Extracellular Vesicle Isolation
EVs were isolated from the blood serum using the Total Exosome Isolation (from serum) reagent
(Invitrogen) according to the manufacturer’s procedure (Figure 1a). Samples were thawed at room
temperature and centrifuged at 2000 g for 30 min to remove cells and debris. Supernatant containing
the clarified serum was transferred to new tubes and placed on ice prior to the procedure. Briefly,
500 µL of serum was mixed with 100 µL of reagent and incubated at 4 ◦C for 30 min. Afterwards,
samples w re c ntrifuged at 10,000 g for 10 min at room temperature. upernatant was discarded,
and the pellet containing EVs was dissolved in 100 µL f PBS buffer. A 1% SDS buffer (100 mM Tris-HCl
pH 8, 50 mM DTT, 1% SDS) was se at the ratio of 1:5 (EVs: buffer) for 10 min at 95 ◦C to l se obtained
EVs and reduce disulfide bonds of released proteins. Lysed EVs were frozen by liquid nitrogen and
stored at −20 ◦C until further processing.
2.3. Protein Dig ti
Samples containing lysed EVs were subjected to digestion by the MED-FASP (Multi-Enzyme
Digestion Filter Aided Sample Preparation) procedure (Figure 1b) [23]. Total protein concentration was
measured using the tryptophan fluorescence-based (WF) assay [25] (see Supplementary Table S1b),
and 100 µg of total protein was transferred to Microcon 30 kDa filters (Merck). 200 µl of the UA buffer
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(8 M urea in 100 mM Tris-HCl pH 8.5) was added to samples onto filters and the filters were centrifuged
at 10,000 g for 20 min at room temperature. This procedure was repeated two times. Cysteine alkylation
was performed by the incubation of samples in darkness at room temperature for 20 min with 100 µL
of 55 mM iodoacetamide solution in the UA buffer followed by centrifugation at 10,000 g for 15 min at
room temperature. Afterwards, samples were washed three times with 100 µL of the UA buffer and two
times with 100 µL of the digestion buffer (50 mM Tris-HCl) by centrifugation in the same conditions.
Three consecutive protein digestions with different enzymes were conducted on filters. First, proteins
were digested overnight with LysC at 1:50 enzyme to protein ratio in the digestion buffer. Peptides were
then eluted by centrifugation at 10,000 g for 15 min at room temperature, followed by two washes with
125 µL and 100 µL of the digestion buffer. Afterwards, filters were placed in new tubes and samples
were subjected to digestion by trypsin overnight at 1:100 enzyme to protein ratio in the digestion buffer.
Peptides were eluted the same way as it was described for the LysC digestion. After placing filters in
new tubes, samples were digested by chymotrypsin for three hours at 1:100 enzyme to protein ratio in
10 mM CaCl2 in 100 mM Tris-HCl pH 7.8. Peptides were eluted by the digestion buffer as described
before. All enzymatic digestion reactions were conducted at 37 ◦C. The peptide concentration was
measured by the WF assay. Aliquots containing 10 µg of peptides resulting from each digestion of
every sample were separately subjected to STAGE (STop And Go Extraction) TIPS procedure [26] using
Empore C18 extraction disks (3M) with elution by 60% acetonitrile/1% acetic acid solution. Samples
were concentrated to 5 µL volume in SpeedVac and stored at −20 ◦C until the MS analysis.
2.4. Mass spectra Acquisition and Data Analysis
Liquid chromatography–tandem mass spectrometry measurements of prepared samples were
performed using a QExactive HF-X mass spectrometer (ThermoFisher Scientific, Palo Alto, CA, USA)
operating in data-dependent acquisition mode, coupled with nanoLC. The raw spectra of all samples
were loaded into the MaxQuant software [27] and searched together against the Homo sapiens
UniProtKB database (June 2016). Peptides were chromatographed on a 50 cm column with 75 µm
inner diameter packed C18 material. Peptide separation was carried out at 300 nL/min for 95 min
using an acetonitrile gradient of 5–30%. The temperature of the column oven was 55 ◦C. The mass
spectrometer operated in data-dependent mode with survey scans acquired at a resolution of 60,000.
Up to the top 15 most abundant isotope patterns with charge ≥ +2 from the survey scan (300–1650 m/z)
were selected with an isolation window of 1.4 m/z and fragmented by HCD with normalized collision
energies of 25. The maximum ion injection times for the survey scan and the MS/MS scans were 20
and 28 ms, respectively. The ion target value for MS1 and MS2 scan modes was set to 3 × 106 and
105, respectively. The dynamic exclusion time was 30 s. Carbamidomethylation was set as a fixed
modification, a maximum of two missed cleavages were allowed, and maximum false discovery rate
for peptides and proteins was set at 0.01. Quantification of protein concentrations was conducted
using the Total Protein Approach [24] and Max Quant LFQ algorithm [28]. The calculations were
performed in Microsoft Excel. Statistical analysis of protein concentrations differing PV patients’ group
and healthy controls’ group was conducted in the Perseus software [29] using the PCA analysis and
student t-test. The functional gene enrichment analysis and Vesiclepedia database [30] search was
performed in the FunRich software [31] using built in FunRich database. The protein interaction
analysis was performed in the STRING database [32]. The mass spectrometry proteomics data have
been deposited to the ProteomeXchange Consortium [33] via the PRIDE [34] partner repository with
the dataset identifier PXD013234.
3. Results
3.1. General Description of Isolated Extracellular Vesicle Material
We identified 624 ± 11 proteins per sample (in total 706); considering only identifications
with at least two peptides, we found 513 ± 10 proteins per sample (see Supplementary Table S1c).
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The concentration range of identified proteins ranges over six orders of magnitude (see Figure 2):
from nmol/mg (e.g., serum albumin, immunoglobulin heavy constant gamma 1) to fmol/mg of
isolated material (e.g., reelin, myosin-14). An issue complicating the analysis of isolated EVs is the
co-precipitation of lipoprotein particles and proteins abundant in the serum, such as serum albumin
and immunoglobulins [35]. The serum albumin content has been reduced to about 12% of the isolated
material, approximately 5-fold decrease in reference to the typical healthy human serum sample [36],
while apolipoproteins were enriched with their content rising to as much as 20% of all present proteins
(see Figure 2).
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We conducted the comparative analysis of identified proteins using the Vesiclepedia database [30]
to determine the EV proteins distribution in our experiments. 466 of 537 recognized by the database
proteins were previously reported in the full Vesiclepedia database (by protein evidence), 451 were
reported in serum/plasma vesicles, and 407 were reported in serum/plasma exosomes. Most of the
unreported proteins belong to the immunoglobulin family. We were able to find 36 out of 100 most
often reported EV proteins as listed by the Vesiclepedia resource, 36 out of 100 proteins most often
reported in serum/plasma vesicles, and 34 in serum/plasma exosomes. We compared our results with
the EV protein markers list presented by C. Théry and K. W. Witwer et al. [35]. We found several
EV specific markers and many of the proteins associated with EVs (see Table 1). The prevalence of
platelet- and monocyte-specific EV protein markers suggests the presence of vesicles related to those
cell types. The absence of some of the most popular exosome markers (e.g., tetraspanins) may indicate
contamination of isolated exosomes with other types of EVs as well as different cell structures, therefore
we refer to the isolated material in general as extracellular vesicles.
Table 1. List of EV protein markers and proteins associated with EV experiments identified in this
study along with their concentrations in PV patients and healthy control samples.
Uniprot Accession Gene Name Protein Name
Median Concentration [pmol/mg]
Controls (N) Patients (PV)
Transmembrane or GPI-anchored proteins associated to plasma membrane and/or endosomes 1
a) Non-tissue specific
P08514 ITGA2B Integrin alpha-IIb (CD41) 1.03 × 10−1 7.57 × 10−2
P05106 ITGB3 Integrin beta-3 (CD61) 5.46 × 10−2 8.54 × 10−2
b) Tissue-specific
P05067 APP Amyloid-beta precursor protein 5.29 × 10−1 1.35
P08571 CD14 Monocyte differentiation antigen CD14 3.14 × 10−1 4.96 × 10−1
P14770 GP9 Platelet glycoprotein IX (CD42a) 8.09 × 10−2 5.77 × 10−2
P08514 ITGA2B Integrin alpha-IIb (CD41) 1.03 × 10−1 7.57 × 10−2
Cytosolic proteins recovered in EVs 1
a) With lipid or membrane protein-binding ability
P04083 ANXA1 Annexin A1 Not quantifiable Not quantifiable
P61586 RHOA Transforming protein RhoA Not quantifiable Not quantifiable
b) Promiscous incorporation in EVs
P60709 ACTB Actin, cytoplasmic 1 3.38 3.84
P63267 ACTG2 Actin, gamma-enteric smooth muscle 2.68 × 10−1 5.59 × 10−1
P04406 GAPDH Glyceraldehyde-3-phosphatedehydrogenase 1.84 × 10−1 2.83 × 10−1
P68366 TUBA4A Tubulin alpha-4A chain 9.78 × 10−2 5.54 × 10−2
P07437 TUBB Tubulin beta chain 1.93 × 10−2 Not quantifiable
Q9H4B7 TUBB1 Tubulin beta-1 chain 2.75 × 10−2 3.77 × 10−3
Major components of non-EV co-isolated structures (abundant in plasma, serum) 1
P02768 ALB Serum albumin 1.67 × 103 1.45 × 103
P02647 APOA1 Apolipoprotein A-I 8.57 × 102 6.53 × 102
P02652 APOA2 Apolipoprotein A-II 1.77 × 102 1.26 × 102
P04114 APOB Apolipoprotein B-100 3.70 × 102 3.29 × 102
Transmembrane, lipid-bound and soluble proteins associated to other intracellular compartments than
PM/endosomes 1
a) Nucleus
P33778 HIST1H2BB Histone H2B type 1-B 8.83 × 10−2 2.73 × 10−1
P62805 HIST1H4A Histone H4 2.98 × 10−1 2.83
b) Secretory pathway (endoplasmic reticulum, Golgi apparatus)
P11021 HSPA5 Endoplasmic reticulum chaperone BiP 4.86 × 10−1 7.16 × 10−1
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Table 1. Cont.
Uniprot Accession Gene Name Protein Name
Median Concentration [pmol/mg]
Controls (N) Patients (PV)
c) Others (autophagosomes, cytoskeleton, ...)
P12814 ACTN1 Alpha-actinin-1 1.89 × 10−1 2.97 × 10−1
Secreted proteins recovered with EVs 1
a) Cytokines and growth factors
Q9GZP0 PDGFD Platelet-derived growth factor D Not quantifiable 8.34 × 10−3
P01137 TGFB1 Transforming growth factor beta-1proprotein 3.47 × 10−1 1.01
b) Adhesion and extracellular matrix proteins
P02765 AHSG Alpha-2-HS-glycoprotein 1.39 × 101 1.07 × 101
O43866 CD5L CD5 antigen-like 7.59 × 101 6.59 × 101
Q99715 COL12A1 Collagen alpha-1(XII) chain 9.68 × 10−3 1.03 × 10−2
P39060 COL18A1 Collagen alpha-1(XVIII) chain 1.33 × 10−1 1.04 × 10−1
P12109 COL6A1 Collagen alpha-1(VI) chain 4.09 × 10−2 2.25 × 10−2
P12111 COL6A3 Collagen alpha-3(VI) chain 8.48 × 10−2 1.37 × 10−1
P02751 FN1 Fibronectin 5.91 × 101 7.78 × 101
Q08380 LGALS3BP Galectin-3-binding protein 5.23 1.07 × 101
1 Protein classification presented here directly refers to EV protein markers list presented by C. Théry and
K. W. Witwer et al. [35].
3.2. Functional Categorization of Identified Proteins
In order to further characterize the isolated proteome, we performed the gene enrichment
analysis on the set of all identified proteins (see Figure 3). As expected, cellular components for
the majority of identifications were determined to be extracellular (63.3%) and exosomes (57.8%).
A substantial part of proteins were localized in lysosomes (35.6%) or cytoskeleton (15.4%), suggesting
co-precipitation of those cellular components with EVs or supposed transportation of protein cargo
related to those structures. About 3% of all identifications were localized in lipoprotein particles.
Even though those proteins represent a small fraction of all identifications, apolipoproteins are among
the highest abundant proteins in the isolated material (as it was discussed in Results Section 3.1.).
Identified proteins were confidently assigned (p-value<0.001) to three biological processes: Protein
metabolism (18.4%), cell growth and/or maintenance (17.9%), and immune response (15%). Prevalent
molecular functions of identified proteins were assigned as transporter activity (8.4%), extracellular
matrix structural constituent (6.2%), complement activity (5.3%), and protease inhibitor activity
(5.3%). Designated biological pathways are closely related to blood components: Hemostasis (24.8%),
immune system (19.5%), clotting cascade (11.4%), platelet activation, signaling and aggregation (11.4%),
and complement cascade (8.9%).
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3.3. Differences in PV Patients’ Exosomal Proteomes
We compared two methods of label-free protein quantification: Total Protein Approach [24] and
MaxQuant LFQ [28]. We quantified only the proteins with at least three razor or unique peptides,
and eight out of nine valid peak intensity values in one of the analyzed study groups (PV patients or
healthy controls). Using this approach, 398 distinct protein groups were quantified (see Supplementary
Table S1d). We performed the principal component analysis of studied samples using quantitative
values obtained using both methods (absolute concentration in pmol/mg from TPA, see Figure 4a,
and LFQ intensity from MQ LFQ, see Figure 4b). We compared protein concentration differences
observed with TPA and MQ LFQ approaches (Supplementary Table S1e). We found that 24 significantly
changed protein titers were common for both methods. The calculated titer ratios correlated with
a Pearson correlation coefficient r = 0.80. Both of those methodologies reveal differences of similar
magnitude between study groups. For a further in-depth quantitative analysis we used absolute
concentration values obtained from TPA.
Approximately 10% of quantified proteins were present at different concentrations (at least 1.5-fold)
between study groups from a student t-test analysis at 5% FDR cutoff: 30 proteins were more abundant
in PV patient samples and eight proteins were less abundant (see Table 2). The presence of higher
abundance of erythrocyte (CD71), platelet (CD42d), and monocyte (CD62L) membrane markers may
suggest an elevated extracellular vesicle count of those cell types in polycythemia vera. This observation
is further supported by elevated leukocyte and platelet counts in PV patients (see Supplementary
Table S1a). Twenty proteins were present at more than 2-fold higher concentrations in PV samples,
and 11 of them higher than 4-fold. Only three proteins had at least 2-fold lower concentrations in
PV samples (see Figure 4c). Five proteins are marked on the volcano plot and their concentration
differences are presented in Figure 4d: Angiogenin (ANG), cathelicidin antimicrobial peptide–CAMP,
heparanase–HPSE, neurogenic locus notch homolog protein 3–NOTCH3, and transferrin receptor
protein 1–TFRC. Overabundance of those proteins suggests deregulation of several different biological
processes in PV, either by excessive numbers of distinct cell types or overstimulation of certain pathways.
The protein that displays the highest difference in concentrations (13-fold) among study groups is the
transferrin receptor protein 1 (TRFC).
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Table 2. Significantly changed proteins from the t-test analysis at 5% FDR along with their concentrations and fractions of total protein in patient and control samples.
Protein Gene p Value [PV]/[N] 1 Peptides Conc. (pmol/mg) Fraction of Total Protein%
N PV N PV
Transferrin receptor protein 1 TFRC 3.30 × 10−4 13 19 0.03 0.46 2.80 × 10−4 3.91 × 10−3
Heparanase HPSE 2.10 × 10−5 11 11 0.05 0.82 3.18 × 10−4 5.00 × 10−3
Plasminogen activator inhibitor 1 SERPINE1 3.90 × 10−3 5.9 6 0.05 0.37 2.39 × 10−4 1.66 × 10−3
Angiogenin ANG 2.00 × 10−5 5.4 3 0.11 0.63 1.83 × 10−4 1.04 × 10−3
Histone H4 HIST1H4A 2.00 × 10−3 5.4 5 0.3 2.83 3.38 × 10−4 3.21 × 10−3
Cathelicidin antimicrobial peptide CAMP 4.60 × 10−6 4.9 5 0.68 3.73 1.31 × 10−3 7.20 × 10−3
Neurogenic locus notch homolog protein 3 NOTCH3 5.30 × 10−3 4.3 8 0.02 0.12 5.62 × 10−4 2.93 × 10−3
Lysozyme C LYZ 2.90 × 10−4 4.2 8 0.82 2.44 1.35 × 10−3 4.03 × 10−3
Histone H3 HIST2H3PS2 1.20 × 10−3 4.2 4 0.28 1.27 4.38 × 10−4 1.96 × 10−3
L-selectin SELL 2.80 × 10−3 4.2 4 0.05 0.21 2.31 × 10−4 8.66 × 10−4
Lactotransferrin LTF 3.70 × 10−3 4 23 0.27 1.09 2.10 × 10−3 8.54 × 10−3
Vinculin VCL 1.20 × 10−3 3.2 13 0.08 0.2 9.44 × 10−4 2.43 × 10−3
Multimerin-1 MMRN1 1.80 × 10−3 3.1 32 0.39 1 5.35 × 10−3 1.38 × 10−2
Beta-2-microglobulin B2M 2.10 × 10−7 2.7 6 2.52 6.83 3.46 × 10−3 9.37 × 10−3
Nidogen-2 NID2 9.80 × 10−3 2.7 6 0.02 0.04 2.57 × 10−4 6.52 × 10−4
Amyloid beta A4 protein APP 3.40 × 10−4 2.6 12 0.53 1.35 4.60 × 10−3 1.18 × 10−2
Serglycin SRGN 1.30 × 10−3 2.4 5 1.51 3.25 2.66 × 10−3 5.73 × 10−3
Platelet glycoprotein V GP5 2.90 × 10−3 2.3 11 0.18 0.57 1.11 × 10−3 3.49 × 10−3
Retinol-binding protein 4 RBP4 2.30 × 10−4 2.1 13 4.65 9.59 1.07 × 10−2 2.21 × 10−2
Lipopolysaccharide-binding protein LBP 7.80 × 10−4 2.1 12 1.44 3.32 7.69 × 10−3 1.77 × 10−2
TGFβ-induced protein ig-h3 TGFBI 2.20 × 10−3 2 12 0.19 0.41 1.41 × 10−3 3.07 × 10−3
Properdin CFP 8.80 × 10−4 1.9 19 6.74 12.83 3.45 × 10−2 6.58 × 10−2
Galectin-3-binding protein LGALS3BP 4.10 × 10−3 1.9 27 5.23 10.74 3.42 × 10−2 7.02 × 10−2
Inter-alpha-trypsin inhibitor heavy chain H3 ITIH3 6.10 × 10−3 1.9 29 1.53 3.15 1.53 × 10−2 3.15 × 10−2
Alpha-1-microglobulin AMBP 2.2 × 10−4 1.8 17 7.75 14.69 3.02 × 10−2 5.73 × 10−2
Platelet factor 4 PF4 5.60 × 10−3 1.8 7 124.41 288.88 1.35 × 10−1 3.13 × 10−1
Complement component C7 C7 2.50 × 10−3 1.7 47 11.11 21.7 1.04 × 10−1 2.03 × 10−1
Complement C1q subcomponent subunit A C1QA 1.20 × 10−3 1.5 18 72.33 114.86 1.88 × 10−1 2.99 × 10−1
Histidine-rich glycoprotein HRG 4.00 × 10−3 1.5 22 18.28 31.2 1.09 × 10−1 1.86 × 10−1
N-acetylmuramoyl-L-alanine amidase PGLYRP2 5.90 × 10−3 1.5 17 2.24 3.37 1.39 × 10−2 2.10 × 10−2
Clusterin CLU 1.10 × 10−3 0.75 19 31.13 23.19 1.63 × 10−1 1.22 × 10−1
Apolipoprotein A-I APOA1 2.70 × 10−3 0.73 41 857.47 652.78 2.64 2.01
Apolipoprotein A-II APOA2 2.40 × 10−3 0.71 11 177.37 126.08 1.98 × 10−1 1.41 × 10−1
Apolipoprotein D APOD 9.60 × 10−4 0.6 13 61.85 37.16 1.49 × 10−1 8.98 × 10−2
Fibulin-1 FBLN1 3.40 × 10−3 0.54 20 3.01 1.63 2.24 × 10−2 1.21 × 10−2
Phosphatidylinositol-glycan-specific phospholipase D GPLD1 4.60 × 10−3 0.5 9 0.19 0.11 1.74 × 10−3 1.04 × 10−3
Peroxiredoxin-6 PRDX6 5.50 × 10−3 0.44 4 4.45 2.93 1.11 × 10−2 7.35 × 10−3
Salivary acidic proline-rich phosphoprotein 1/2 PRH1 2.90 × 10−3 0.3 3 0.19 0.06 3.23 × 10−4 1.01 × 10−4
1 Fold change (Patients [PV]/Controls [N].
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Figure 4. Results of statistical t-test analysis conducted for two groups of samples: PV patient
samples and healthy volunteer samples: PCA plots for study samples created from the results of two
computational quantitative approaches, (A) the TPA and (B) Max Quant LFQ quantification; (C) the
volcano plot showing the experimental outlier proteins (38 proteins); (D) concentration plot of six outlier
proteins differentiating across the samples (angiogenin–ANG, cathelicidin antimicrobial peptide–CAMP,
heparanase—HPSE, neurogenic locus notch homolog protein 3–NOTCH3, and transferrin receptor
protein 1—TFRC).
We performed an interaction analyses of proteins significantly differing between patient and
control groups using the STRING database [32] to seek potential relations between them. Both more
abundant proteins and less abundant proteins constituted networks of significantly more interactions
than expected from random sets of proteins (PPI enrichment values of lower than 1.0 × 10−16 and
2.78 × 10−7, respectively; see Figure 5). Only three out of 30 proteins enriched in PV samples are
absent from the constructed interaction network. Key Reactome database [37] pathways are presented
using different node colors on the created network (Figure 5). The network can be visibly divided into
two smaller tightly connected systems. The first one is related to the immune response and partly
Proteomes 2019, 7, 20 12 of 17
to related neutrophil degranulation (see yellow and dark green nodes in Figure 5a). Upregulation of
those pathways may be explained by leukocytosis, JAK2 activation, or excess of granulocytes reported
in PV cases [22]. Many proteins or genes from the described system have been previously found to be
more abundant or upregulated in PV. Two of those proteins were mentioned previously as the volcano
plot outliers (see Figure 4c,d): CAMP and HPSE. The other visible net of interactions is associated with
platelet degranulation, activation, signaling and aggregation, and hemostasis (see red and blue nodes
in Figure 5a). The presence of such interaction pathways is expected in PV, which is characterized
by the persistent platelet activation and excessive cell adhesiveness [22]. The network for proteins
present at lower concentrations in PV samples constituted of five out of eight proteins (see Figure 5b).
The main characteristics of these proteins are constituents of lipoprotein particles, lipoprotein particle
receptor binding, and reverse cholesterol transport (APOAI, APOAII, CLU) and cholesterol binding
(APOAI, APOAII, APOD).
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Figure 5. Interaction networks of proteins present at statistically significant different concentrations
in PV samples inferred from the t-test at 5% FDR built using the STRING database. Proteins absent
from the networks are not shown. (A) Interaction network of proteins present at higher
concentrations in PV samples. Colors of nodes designate involvement in assigned Reactome pathways:
Red–platelet degranulation, blue–platelet activation, signaling and aggregation, light green–hemostasis,
yellow–innate immune system, purple–amyloid fiber formation, and dark green–neutrophil
degranulation; (B) interaction network of proteins present at lower concentrations in PV samples.
4. Discussion
Polycythemia vera, one of the Philadelphia chromosome negative myeloproliferative neoplasms,
is characterized by increased bone marrow hematopoiesis, resulting in the overproduction of
erythrocytes, and frequently also of platelets and leukocytes. A typical complication of this disorder
is thrombosis, which is a result of the hypercoagulable state associated with excessive amounts of
blood cells and inflammatory response [20–22]. PV is associated with persistent enhanced platelet
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activation. When activated, platelets release extracellular vesicles: Mainly procoagulant microvesicles
and exosomes [12]. In our work, we isolated and studied EV-enriched sera of PV patients in comparison
to healthy volunteers. EVs, such as exosomes, are one of the main channels of inter-cell communication.
Although it is known that the previously reported excess of extracellular vesicles released from
cell membranes of activated or apoptotic blood cells directly contribute to thrombosis through
their procoagulant activity [12–14], the exact proteomic composition of these vesicles has not been
investigated previously. The exact mechanisms of polycythemia vera occurrence, course, and possible
leukemic transformation are not known. By studying proteomes of extracellular vesicles released in
PV, we managed to get a closer look into the secondary systemic effects of the disease. We identified
the main protein components of EVs deregulated in PV, which were related with excessive amounts of
cells (TFRC, SELL, GP5), increased platelet activation (SERPINE1, MMRN1), elevated immune and
inflammatory response (HPSE, CAMP, LYZ, SELL, LTF), high concentrations of procoagulant and
angiogenic agents (ANG, HPSE), as well as oncogenic proteins (NOTCH3).
We have found higher concentrations of erythrocyte, platelet, and leukocyte surface membrane
markers, supporting previous discoveries of the abundance of those blood cells in PV [22]. This finding
was also verified by PV patients’ leukocyte and platelet elevated counts (Supplementary Table S1a),
together suggesting the prevalence of serum EVs related to those cell types. Transferrin receptor protein
1 (TFRC, CD71), a reticulocyte marker, was found to be as much as 13-fold more abundant in samples
of PV patients, illustrating massive erythrocyte overproduction in the disease. During reticulocyte
maturation, TFRC is removed to exosomes [1]. One of the megakaryocyte membrane markers,
translocated to platelets upon their release, is platelet glycoprotein V (GP5, CD42d); here, found to be
more than two times more abundant in PV samples. About one third of proteins identified at higher
concentrations in PV were associated with platelet degranulation, activation, signaling, and aggregation
(APP, HRG, ITIH3, LGALS3BP, MMRN1, PF4, SERPINE1, SRGN, VCL), and most of them were tightly
connected in the interaction network (Figure 5a). Plasminogen activator inhibitor 1 (SERPINE1) was
almost 6-fold more abundant in PV samples, and its mRNA was previously reported to be upregulated
in PV and associated with thrombotic risk and inflammatory pathways [38]. Multimerin-1 (MMRN1) is
also tightly associated with platelet release as a component of the thrombopoietin receptor. Surprisingly,
one of the higher abundant proteins, serglycin (SRGN) was previously reported as a marker of AML,
not upregulated in PV, and therefore allowing distinction between those two blood disorders [39].
However, there are reports of interaction between serglycin and lysozyme [40], which indicate that their
concentrations could be correlated in this instance. Even more proteins present at higher concentrations
in PV take part in immune response (APP, B2M, C1QA, C7, CAMP, CFP, HPSE, LBP, LTF, LYZ, SELL,
VCL). L-selectin (SELL, CD62L), closely related to the granulocyte count, was present at more than
four times higher concentrations in PV samples. Lysozyme and lactotransferrin concentrations were
previously reported to be elevated in the serum of PV patients [40,41]. Moreover, lysozyme may
be stored in megakaryocytes, which seem to be present in excessive amounts in PV as their marker
CD42d is increased, as well as overall platelet count. Cathelicidin (CAMP) is associated with granules
released upon platelet activation, which closely correlates with inflammatory response activation in PV
patients. Lipopolysaccharide-binding protein (LBP) interacts with CAMP and is similarly involved in
the immune response. Beta-2-microglobulin is a component of MHC I class molecules. Its level may be
raised in myeloproliferative neoplasms [42]. Another key protein, heparanase (HPSE) was previously
reported to be present at higher concentrations in PV bone marrow biopsies [43], is associated with
myelofibrosis and displays procoagulant and angiogenic activity. HPSE concentration in PV patient
samples was elevated more than 11-fold. Increased HPSE activity is associated with the formation of
blood borne tumor metastases. Other upregulated angiogenic proteins are, e.g., ANG, HRG, or ITIH3.
Angiogenin (ANG) promotes angiogenesis and tumor growth and was found to be overexpressed in
leukemia [44]. Its concentration was elevated more than 5-fold in PV patients. One more significant
protein, absent from previously described pathways is the neurogenic locus notch homolog protein
3 (NOTCH3), found at more than 4-fold increased concentrations in PV samples. NOTCH3 was
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previously found to be overexpressed in several types of cancers [45]. Its excessive concentration in
the serum is correlated with hypertrophy of smooth muscle cells in blood vessels as a major cause
of the CADASIL syndrome (cerebral autosomal dominant arteriopathy with subcortical infarcts and
leukoencephalopathy) [46].
In order to easily isolate extracellular vesicles in high concentrations, we used a precipitation kit,
employing the methodology applied and validated before in a number of EV studies [47,48]. In order
to remain impartial to experimental results, we focused on the in-depth wide proteomic analysis of
the material instead of antibody-based targeted tests. A limitation of our study is the lack of detailed
characterization of isolated EVs, which could further improve the understanding of their protein
cargo importance in the disease. Using our approach, we have identified a number of EV-related
proteins, accompanied by high concentrations of reportedly co-precipitated structures’ components, e.g.,
serum albumin, apolipoproteins. In fact, most of the proteins present at lower concentrations in PV were
associated with lipoprotein particles (APOAI, APOAII, APOD, CLU). Obviously, the presence of those
proteins in the isolated EV material is unwelcome, and the problem with lipoprotein contamination of
exosomes has been reported before [35]. Nevertheless, the fact that those proteins were less abundant
in PV patients may be associated with reports of hypocholesterolemia occurring in PV, associated
with a drop in apolipoprotein A-I and B concentrations and possible sequestration of cholesterol to
overabundant erythrocytes [49]. Similarly, to apolipoproteins, the presence of histones in the isolated
material was not fully anticipated; yet, their upregulation in PV samples could be linked to the
upregulation of apoptotic pathways in the disease. However, as the process of protein co-precipitation
with EVs is not fully understood, the role of reportedly contaminating proteins in the disease can only
be a subject of assumptions.
The pathophysiology of polycythemia vera is still to be delineated: As we have shown in this
work, extracellular vesicles, the communication vectors between cells, carry an abundance of versatile
protein cargo. Studied here EVs proteome is associated with crucial processes, which undergo in blood
cells and their surroundings, such as cell proliferation and differentiation, immune and inflammatory
response, or tumor creation and its environment regulation by angiogenesis.
Supplementary Materials: The following are available online at http://www.mdpi.com/2227-7382/7/2/20/s1,
Table S1: Mass spectrometry data: (a) Blood data of PV patients, (b) concentration of isolated EV samples and
the total amount of protein content isolated, (c) list of all identified proteins along with their concentrations in
samples, (d) results of the statistical t-test analysis, (e) comparison of TPA and MQ LFQ methodologies on proteins
significantly differing in concentration between analyzed groups.
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